
OTLK Stock Forecast & Price Target
OTLK Analyst Ratings
Bulls say
Outlook Therapeutics Inc has demonstrated substantial investment in its growth, with general and administrative expenses rising 106.2% year-over-year to $11.9 million, reflecting the company's commitment to scaling operations. The ongoing success of the ONS-5010 program, particularly indicated by noninferiority results to ranibizumab in the NORSE EIGHT trial, positions the product favorably in a competitive market and may enhance future revenue prospects. Furthermore, strategic collaborations, such as the partnership with Cencora for commercial launch support, signify potential for expanded market reach and operational sustainability, reinforcing a positive outlook for the company's financial trajectory.
Bears say
Outlook Therapeutics Inc. reported a significant financial setback in 1Q24, with a loss per share of $0.78 and a widening operating loss of $21.6 million, which exceeded earlier estimates. The company’s failure to meet the pre-specified non-inferiority endpoint in the NORSE EIGHT clinical study raises concerns about the viability of ONS-5010, further compounded by the potential for regulatory hurdles that could delay its approval. Additionally, the adjustment of the EV/Sales multiple from 7.5x to 3.5x and the resultant reduction in price target indicate a deteriorating financial outlook and potential for further share dilution through equity financing.
This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OTLK Analyst Forecast & Price Prediction
Start investing in OTLK
Order type
Buy in
Order amount
Est. shares
0 shares